Please assess the completion status of the following clinical trial:

Trial Title: Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Established diagnosis of Systemic SOJIA according to ILAR criteria for at least six months before the study entry, with inadequate response or intolerance to standard therapy with oral steroids and/or methotrexate, with or without previously used biologic agents.~2. Active disease for at least one month prior to enrolment as defined by the following criteria:~   * Presence of arthritis plus at least one of the following:~     * Fever, defined as a body temperature \>= 37,5 C degree at least once a day during at least five consecutive days or presence of typical SOJIA intermittent temperature chart~    * Rash, defined by presence of typical SOJIA salmon pink rash on the trunk and elsewhere during the febrile episodes~    * Serositis (pericarditis, pleuritis, peritonitis) confirmed by ultrasound and/or X-ray exploration or by presence of typical ECG findings in the case of pericarditis~    * Lymphadenopathy, defined by lymph nodes enlargement to 1,5 cm or more localized anywhere within the body, and/or hepatomegaly and/or splenomegaly, confirmed by ultrasound evaluation and established after comparison to age standards for organ size~    * ESR \>= 20 mm/h (first hour) and/or CRP \>= 10 mg/L. in the absence of arthritis, two definite or one definite and one probable diagnostic criteria plus ESR \>=20 mm/h (first hour) and/or CRP \>=10 mg/L~3. Age at enrolment between 2 and 25 years~4. Age at first SOJIA diagnosis \< 16 years~5. Previously introduced standard treatment of disease with steroids without satisfactory effect and concomitant treatment with oral steroids at a dose equivalent to \>= 0,2 mg/kg/day of prednisolone, unmodified for at least four weeks before patient's enrolment~6. In case of concomitant methotrexate treatment, it has to be on stable dose \>= 10mg/m2 weekly for al least 4 weeks before pt enrollment~7. Previous treatment with biologics, if any, during at least three months without satisfactory effect or with drug intolerability, discontinued for at least the period specified below before patient's enrolment:~   * Two months for etanercept~  * Six months for infliximab~8. Other disease-modifying anti-rheumatic drugs possibly previously introduced have to be discontinued for a period of at least five half lives~9. Concomitant nonsteroidal anti-inflammatory drugs, if any, on a stable dose for at least four weeks before patient's enrolment~10. Female of childbearing potential, using safe contraceptive measures~11. Signed written informed consent before starting any study procedure~Exclusion Criteria:~1. Ongoing clinical relevant viral infection (eg.: Herpes Zoster, Ebstein barr, CMV, Systemic fungal infections or history of recurrent serious bacterial infection)~2. History of macrophage activation syndrome~3. Clinically significant illness i.e. any condition (including laboratory abnormalities) that in the opinion of the Investigator places the patient to unacceptable risk for adverse outcome if he/she were to participate in the study~4. Psychiatric illness/social situations that would limit compliance with study medication and protocol requirements~5. Congenital heart and/or central nervous system disorders~6. Inherited metabolic diseases~7. Positive serological testing for anti HCV, anti HIV and HBsAg (to be performed at screening)~8. Pregnant or lactating women~9. Presence of malignancy~10. Any previous evidence, irrespective of its severity, of coronary disease, cardiac rhythm abnormalities or congestive heart failure~11. QTc interval \> 450 msec at screening evaluation~12. Serum magnesium and potassium below the LLN at screening~13. Unavoidable concomitant treatment with any drug known for potential risk of causing Torsades de Pointes

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- ITF2357 (Type: EXPERIMENTAL): ITF2357 hard gelatine capsules were administered orally, in fed conditions, at the cumulative daily dose of 1.5 mg/kg achieved by administration of 0.75 mg/kg at 12-hour interval for 4 weeks initially. The doses of 1.5 mg/kg/day were achieved by administration of an appropriate number of capsules of definite strength (dose strengths of 7.5, 10, 12.5, 15, 20 mg and 50 mg).~Treatment was further prolonged up to 12 weeks in total if so suggested by the observed benefits and the lack of treatment-limiting toxicity

Based on this trial design, predict the completion outcome and termination type (if applicable).